Literature DB >> 11330336

Effects of repeated systemic administration of d-Fenfluramine on serotonin and glutamate release in rat ventral hippocampus: comparison with methamphetamine using in vivo microdialysis.

C Rocher1, A M Gardier.   

Abstract

We compared the effects of three systemic injections of various doses of d-Fenfluramine, an indirect serotonergic agonist (1.3, 5 or 10 mg/kg), to those of a known neurotoxin, methamphetamine (METH, at a 7.5 mg/kg dose), given i.p. at 2-h intervals, simultaneously on extracellular levels of glutamate [Gluext] and 5-HT [5-HText] in the ventral hippocampus (VHPC) using in vivo microdialysis in conscious rats. METH markedly increased both [Gluext] (+77% over the control value in saline-treated rats) and [5-HText] (around +250% over controls) in the VHPC. d-Fenfluramine, at all the doses studied, induced gradual increases of [5-HText] in the VHPC (between +125% and +417% over control values), but did not modify [Gluext]. These data highlight marked in vivo differences between METH and d-Fenfluramine in their effects on extracellular levels of 5-HT and Glu in the rat ventral hippocampus following their repeated systemic administration.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11330336     DOI: 10.1007/s002100000381

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  23 in total

Review 1.  Causes and consequences of methamphetamine and MDMA toxicity.

Authors:  Maria S Quinton; Bryan K Yamamoto
Journal:  AAPS J       Date:  2006-05-12       Impact factor: 4.009

2.  mGluR5 antagonism attenuates methamphetamine reinforcement and prevents reinstatement of methamphetamine-seeking behavior in rats.

Authors:  Justin T Gass; Megan P H Osborne; Noreen L Watson; Jordan L Brown; M Foster Olive
Journal:  Neuropsychopharmacology       Date:  2008-09-17       Impact factor: 7.853

Review 3.  Amphetamine toxicities: classical and emerging mechanisms.

Authors:  Bryan K Yamamoto; Anna Moszczynska; Gary A Gudelsky
Journal:  Ann N Y Acad Sci       Date:  2010-02       Impact factor: 5.691

4.  Effects of sequential ethanol exposure and repeated high-dose methamphetamine on striatal and hippocampal dopamine, serotonin and glutamate tissue content in Wistar rats.

Authors:  Atiah H Almalki; Sujan C Das; Fahad S Alshehri; Yusuf S Althobaiti; Youssef Sari
Journal:  Neurosci Lett       Date:  2017-11-22       Impact factor: 3.046

5.  Meth math: modeling temperature responses to methamphetamine.

Authors:  Yaroslav I Molkov; Maria V Zaretskaia; Dmitry V Zaretsky
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2014-02-05       Impact factor: 3.619

6.  Effects of chronic unpredictable stress and methamphetamine on hippocampal glutamate function.

Authors:  Jamie Raudensky; Bryan K Yamamoto
Journal:  Brain Res       Date:  2007-01-02       Impact factor: 3.252

7.  MDMA produces a delayed and sustained increase in the extracellular concentration of glutamate in the rat hippocampus.

Authors:  John H Anneken; Gary A Gudelsky
Journal:  Neuropharmacology       Date:  2012-07-25       Impact factor: 5.250

8.  Differential behavioral syndrome evoked in the rats after multiple doses of SSRI fluoxetine with selective MAO inhibitors rasagiline or selegiline.

Authors:  Z Speiser; T Fine; L Litinetsky; S Eliash; E Blaugrund; S Cohen
Journal:  J Neural Transm (Vienna)       Date:  2007-09-07       Impact factor: 3.575

9.  Effects of a single postnatal methamphetamine administration on NMDA-induced seizures are sex- and prenatal exposure-specific.

Authors:  Romana Slamberová; Barbora Schutová; Iveta Matejovská; Klára Bernásková; Richard Rokyta
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2009-05-14       Impact factor: 3.000

Review 10.  The role of oxidative stress, metabolic compromise, and inflammation in neuronal injury produced by amphetamine-related drugs of abuse.

Authors:  Bryan K Yamamoto; Jamie Raudensky
Journal:  J Neuroimmune Pharmacol       Date:  2008-08-15       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.